Members of the Texas Drug Utilization Review (DUR) Board meet quarterly in Austin to promote safety through an increased review and awareness of outpatient prescribed drugs. Members recommend medical criteria, standards, and educational intervention methods used in Texas Medicaid. The board reviews and approves the therapeutic criteria for prospective and retrospective drug utilization as well as clinical prior authorization criteria. In addition, members also recommend drugs for inclusion in the Medicaid preferred drug list, considering the drug's clinical efficacy, safety, cost-effectiveness, and program benefits.
Please review the written and public testimony procedures prior to submitting information to board members.
By Regular/Overnight Mail
Texas Drug Utilization Review Board (MC-2250)
Texas Health and Human Services
4900 North Lamar Blvd.
Austin, TX 78751
This address is only for issues pertaining to the Texas DUR board. Messages received off-cycle or unrelated to the business of the board are not accepted.
February 11, 2021
Revised Hepatitis C Drug Prior Authorization Forms Now Available
February 3, 2021
Clinical Prior Authorization Assistance Chart Now Available
February 2, 2021
January 2021 Drug Utilization Review Board Meeting Summary
January 29, 2021
Clinical Prior Authorization Updates for Cystic Fibrosis Agents
January 28, 2021
January 2021 Preferred Drug List Now Available
January 4, 2021
Desmopressin Clinical Prior Authorization Revision
January 4, 2021
Having Trouble Viewing or Downloading a Form?